There have been 50 recent insider transactions recorded for Arbutus Biopharma Corporation (ABUS), including 31 buys and 10 sells. Total insider buying was valued at $16.12M and total insider selling at $528.88K.
Notable insiders with recent activity include Androski Lindsay, Nguyen Tuan, Sawhney Roger. Insider transactions can provide insights into how company leadership views the stock's valuation and future prospects.
Insider Transactions — ABUS
| Date |
Name |
Role |
Transaction |
Shares |
Avg. Price |
Value |
Shares Owned |
| 2026-02-02 |
Androski Lindsay |
President and CEO |
RSU Award |
28,000 |
- |
- |
28,000 |
| 2026-02-02 |
Nguyen Tuan |
Chief Financial Officer |
RSU Award |
73,500 |
- |
- |
73,500 |
| 2025-08-04 |
Sawhney Roger |
Director |
Unknown |
- |
- |
- |
- |
| 2025-08-04 |
Sawhney Roger |
Director |
RSU Award |
157,600 |
$3.34 |
$526.38K |
157,600 |
| 2025-03-31 |
Nguyen Tuan |
Chief Financial Officer |
RSU Award |
750,000 |
$3.50 |
$2.63M |
750,000 |
| 2025-03-31 |
Nguyen Tuan |
Chief Financial Officer |
RSU Award |
750,000 |
$3.49 |
$2.62M |
750,000 |
| 2025-03-28 |
Nguyen Tuan |
Officer |
Unknown |
- |
- |
- |
- |
| 2025-03-18 |
Beardsley Robert A |
Director |
RSU Award |
157,600 |
$3.20 |
$504.32K |
157,600 |
| 2025-03-18 |
Androski Lindsay |
President and CEO |
RSU Award |
310,422 |
$3.20 |
$993.35K |
310,422 |
| 2025-03-18 |
Hasija Anuj |
Director |
RSU Award |
157,600 |
$3.20 |
$504.32K |
157,600 |
| 2025-02-24 |
Beardsley Robert A |
Director |
Unknown |
- |
- |
- |
- |
| 2025-02-24 |
Gline Matthew |
10 Percent Owner |
Unknown |
- |
- |
- |
38,847,462 |
| 2025-02-24 |
Androski Lindsay |
President and CEO |
Unknown |
- |
- |
- |
- |
| 2025-02-24 |
Hasija Anuj |
Director |
Unknown |
- |
- |
- |
- |
| 2025-02-24 |
Bishop Joseph E |
Director |
Unknown |
- |
- |
- |
- |
| 2025-02-14 |
Hastings David C |
Chief Financial Officer |
RSU Award |
90,100 |
- |
- |
249,824 |
| 2025-02-14 |
Naftzger J. Christopher |
General Counsel and Cco |
RSU Award |
54,300 |
- |
- |
140,544 |
| 2025-02-14 |
Mcelhaugh Michael J. |
Interim President & CEO |
RSU Award |
718,800 |
$3.29 |
$2.36M |
718,800 |
| 2025-02-14 |
Sims Karen |
Chief Medical Officer |
RSU Award |
49,300 |
- |
- |
155,494 |
| 2025-02-04 |
Hastings David C |
Chief Financial Officer |
Informative Sell |
22,183 |
$3.28 |
$72.83K |
159,724 |
| 2025-02-04 |
Naftzger J. Christopher |
General Counsel and Cco |
Informative Sell |
11,333 |
$3.28 |
$37.21K |
86,244 |
| 2025-02-04 |
Mcelhaugh Michael J. |
Interim President & CEO |
Informative Sell |
23,790 |
$3.28 |
$78.1K |
1,481,003 |
| 2025-02-04 |
Sims Karen |
Chief Medical Officer |
Informative Sell |
19,348 |
$3.28 |
$63.52K |
106,194 |
| 2024-08-14 |
Manchester Keith S |
Director |
Option Exercise (Sell) |
54,915 |
$0.56 |
$30.75K |
- |
| 2024-05-23 |
Henriques Richard C Jr |
Director |
RSU Award |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Burgess Daniel D |
Director |
RSU Award |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Manchester Keith S |
Director |
RSU Award |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Meyers James R |
Director |
RSU Award |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Torti Frank |
Director |
RSU Award |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-05-23 |
Rewolinski Melissa |
Director |
RSU Award |
67,000 |
$3.28 |
$219.76K |
67,000 |
| 2024-02-02 |
Hastings David C |
Chief Financial Officer |
Informative Sell |
9,593 |
$2.31 |
$22.18K |
181,907 |
| 2024-02-02 |
Sofia Michael J. |
Chief Scientific Officer |
Informative Sell |
9,982 |
$2.31 |
$23.08K |
1,485,121 |
| 2024-02-02 |
Mcelhaugh Michael J. |
Interim President & CEO |
Informative Sell |
10,164 |
$2.31 |
$23.5K |
1,504,793 |
| 2024-02-02 |
Sims Karen |
Chief Medical Officer |
Informative Sell |
4,358 |
$2.31 |
$10.08K |
125,542 |
| 2024-02-01 |
Hastings David C |
Chief Financial Officer |
RSU Award |
112,500 |
- |
- |
191,500 |
| 2024-02-01 |
Naftzger J. Christopher |
General Counsel and Cco |
RSU Award |
95,100 |
- |
- |
95,100 |
| 2024-02-01 |
Sofia Michael J. |
Chief Scientific Officer |
RSU Award |
437,800 |
$2.40 |
$1.05M |
437,800 |
| 2024-02-01 |
Mcelhaugh Michael J. |
Interim President & CEO |
RSU Award |
495,100 |
$2.40 |
$1.19M |
495,100 |
| 2024-02-01 |
Sims Karen |
Chief Medical Officer |
RSU Award |
101,000 |
- |
- |
129,900 |
| 2023-07-12 |
Rewolinski Melissa |
Director |
Unknown |
- |
- |
- |
- |
| 2023-07-12 |
Rewolinski Melissa |
Director |
RSU Award |
110,000 |
$2.27 |
$249.7K |
110,000 |
| 2023-07-10 |
Naftzger J. Christopher |
Officer |
Unknown |
- |
- |
- |
- |
| 2023-07-10 |
Naftzger J. Christopher |
General Counsel and Cco |
RSU Award |
500,000 |
$2.26 |
$1.13M |
500,000 |
| 2023-07-10 |
Sims Karen |
Chief Medical Officer |
Disposition |
57,800 |
$2.90 |
$167.62K |
- |
| 2023-07-10 |
Sims Karen |
Chief Medical Officer |
RSU Award |
153,640 |
$2.26 |
$347.23K |
153,640 |
| 2023-05-24 |
Henriques Richard C Jr |
Director |
RSU Award |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Burgess Daniel D |
Director |
RSU Award |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Manchester Keith S |
Director |
RSU Award |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Meyers James R |
Director |
RSU Award |
55,000 |
$2.56 |
$140.8K |
55,000 |
| 2023-05-24 |
Torti Frank |
Director |
RSU Award |
55,000 |
$2.56 |
$140.8K |
55,000 |
■ Informative Buy/Sell — open market transaction (most significant)
■ Uninformative Buy — award, option exercise, conversion
■ Uninformative Sell — tax withholding, award vest sale
■ Neutral — gift, trust, expiry
